RefleXion Treats First Cancer Patient with SCINTIX Biology-Guided Radiotherapy

RefleXion Medical announced the first patient has finished treatment with SCINTIC biology-guided radiotherapy on its RefleXion X1 machine at the Stanford Medicine Cancer Center.
 
SCINTIX is a radiopharmaceutical-directed treatment for early and late-stage cancers. It uses individual tumor biology to drive its own treatment.
 
It uses emissions from cancer cells that are made by injecting the patient with a radiopharmaceutical to deliver a radiation dose that continuously and autonomously targets the cancer. This capability also “lights up” all indicated cancer targets in the body during treatment.
 
According to RefleXion, the X1 with SCINTIX is the only dual-treatment modality radiotherapy platform in the world that can treat patients with indicated solid tumors of any stage.
 
“We are elated that Stanford Medicine is the first healthcare provider to deliver SCINTIX treatment, marking the first delivery of autonomous radiotherapy,” Sam Mazin, Ph.D., founder and CTO of RefleXion, told the press. “We have been working toward this milestone for over a decade, and on behalf of everyone at RefleXion, I want to thank our early adopter clinical sites, numerous advisors, and our investors for working alongside us to develop and bring to market this new option for patients with all stages of solid tumors.”
 
The FDA cleared SCINTIX to treat lung and bone tumors, which may arise from primary cancers or metastatic lesions spread from other cancers in the body. SCINTIX was previously designated as a Breakthrough Device to treat lung tumors because of its potential to precisely manage tumor motion.
 
RefleXion said over the next several weeks, multiple renowned U.S. cancer centers will begin offering SCINTIX therapy. This includes the City of Hope Comprehensive Cancer Center in Southern California, and sites in Pennsylvania and Texas. By the end of 2023, the company said SCINTIX will also be available in New Jersey, Connecticut, and Oregon.
 
“This first SCINTIX treatment is a watershed moment for physicians and patients alike because finally, we have a technology with the potential to meet the challenges of treating metastatic disease head on,” said Todd Powell, president and CEO of RefleXion. “Clinical literature and emerging practice guidelines are beginning to incorporate the importance of treating all visible disease in certain cancers. SCINTIX was conceived with that end in mind, and to work in combination with drug therapies to improve outcomes, especially for patients with advanced-stage cancers.”